- Home
- INMB vs VRCA Comparison
INMB vs VRCA Comparison
Compare INMB & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INMB
- VRCA
- Stock Information
- Founded
- INMB 2015
- VRCA 2013
- Country
- INMB United States
- VRCA United States
- Employees
- INMB N/A
- VRCA N/A
- Industry
- INMB Biotechnology: Pharmaceutical Preparations
- VRCA Biotechnology: Pharmaceutical Preparations
- Sector
- INMB Health Care
- VRCA Health Care
- Exchange
- INMB Nasdaq
- VRCA Nasdaq
- Market Cap
- INMB 68.9M
- VRCA 58.7M
- IPO Year
- INMB 2019
- VRCA 2018
- Fundamental
- Price
- INMB $2.53
- VRCA $5.96
- Analyst Decision
- INMB Buy
- VRCA Hold
- Analyst Count
- INMB 4
- VRCA 5
- Target Price
- INMB $9.53
- VRCA $60.00
- AVG Volume (30 Days)
- INMB 2.9M
- VRCA 54.3K
- Earning Date
- INMB 08-07-2025
- VRCA 08-12-2025
- Dividend Yield
- INMB N/A
- VRCA N/A
- EPS Growth
- INMB N/A
- VRCA N/A
- EPS
- INMB N/A
- VRCA N/A
- Revenue
- INMB $50,000.00
- VRCA $14,704,000.00
- Revenue This Year
- INMB $212.27
- VRCA $165.25
- Revenue Next Year
- INMB $10,184.28
- VRCA $80.06
- P/E Ratio
- INMB N/A
- VRCA N/A
- Revenue Growth
- INMB N/A
- VRCA 5.72
- 52 Week Low
- INMB $1.89
- VRCA $3.82
- 52 Week High
- INMB $11.64
- VRCA $34.30
- Technical
- Relative Strength Index (RSI)
- INMB 41.61
- VRCA 42.31
- Support Level
- INMB $2.42
- VRCA $5.29
- Resistance Level
- INMB $2.61
- VRCA $7.40
- Average True Range (ATR)
- INMB 0.22
- VRCA 0.64
- MACD
- INMB 0.09
- VRCA -0.01
- Stochastic Oscillator
- INMB 26.67
- VRCA 31.75
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.